# Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

> **NCT00486954** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 273 (actual)

## Conditions studied

- Neoplasms, Gastrointestinal Tract

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00486954
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-10
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00486954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00486954, "Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00486954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*